Lower Cardiorenal Risk with SGLT2 Inhibitor vs. DPP4 Inhibitor in Type 2 Diabetes Patients Without Established Cardiovascular and Renal Diseases

Konferenzabstract für die Kidney Week, veröffentlicht im "Journal of the American Society of Nephrology"

Autor:innen

Kåre I. Birkeland, Johan Bodegård, Amitava Banerjee, Dae Jung Kim, Jan W. Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack, Jil Billy Mamza, Ruiqi Zhang, Toshitaka Yajima, Issei Komuro, Takashi Kadowaki